DOTA-cTMTP1
DOTA-cTMTP1 is a cyclic tumor-homing peptide precursor molecule. DOTA-cTMTP1 selectively binds to XPNPEP2 on highly metastatic tumor cells, accumulates and retains in hepatocellular carcinoma tumors, and maintains a high tumor-to-liver contrast over time in small animal models. After radiolabeling with 68Ga, DOTA-cTMTP1 forms a PET probe for positron emission tomography (PET) imaging of hepatocellular carcinoma (HCC).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C55H92N20O21S2
- Masse moléculaire:1433.57
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform Radionuclide-Drug Conjugates (RDCs)
More
Activité biologique
DOTA-cTMTP1 (20 μg; 10 min) exhibits > 99% radiolabeling efficiency when incubated with [68Ga]GaCl3 at 95 °C for 10 min, producing [68Ga]Ga-DOTA-cTMTP1 with a specific activity of 5.19 MBq/nmol[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
[68Ga]Ga-DOTA-cTMTP1 (i.v.; single dose) enables clear visualization of small HCC lesions in a transgenic mouse model, with increasing tumor-to-liver ratios over 120 min postinjection[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (male, 5-6 weeks old, ~20 g)[1]
-
Dosage:5.2 MBq
-
Administration:i.v.; single dose
-
Result:Reached tumor uptake of 1.3 %ID/g at 15 min, 1.09 %ID/g at 30 min, and 0.74 %ID/g at 150 min postinjection.
Showed tumor uptake of 0.98 %ID/g at 30 min with retention at later time points.
Achieved tumor-to-liver ratios of 2.65 at 30 min, 2.37 at 60 min, 2.14 at 120 min, and 2.69 at 150 min.
Reached tumor-to-muscle ratio of 11.17 at 150 min.
Reduced tumor uptake to 0.36 %ID/g at 30 min and 0.32 %ID/g at 60 min after coinjection of unlabeled TMTP1.
Decreased blood radioactivity from 1.11 %ID/g at 30 min to 0.48 %ID/g at 60 min, and then to 0.22 %ID/g at 120 min.
Chemical Information
-
Masse moléculaire 1433.57
-
Formule C55H92N20O21S2
-
Sequence
DOTA-Gly-Gly-Gly-Cys-Gly-Asn-Val-Val-Arg-Gln-Gly-Cys (Disulfide bridge: Cys1-Cys9)
-
Sequence Shortening
DOTA-GGG-CGNVVRQGC (Disulfide bridge: Cys1-Cys9)
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
DOTA-cTMTP1 Related Classifications
HY-P11816 Related Classifications
Powered by Bioz